Development of Continuous C-Peptide Monitoring Technologies Grant

Development of Continuous C-Peptide Monitoring Technologies Grant

Status: ACTIVE
Funder: Breakthrough T1D ( Formally JDRF International)
Amount: Up to US $900,000
Last Updated: October 16, 2025

Summary

Breakthrough T1D invites innovative applications for the development of continuous C-peptide monitoring technologies. This initiative will support early-stage sensor technology development, preclinical studies, and initial clinical evaluations. Funding of up to $900,000 is available over a maximum of three years, with larger budgets considered upon strong justification. Letters of Intent from academic and industry researchers are encouraged, particularly for projects that enhance C-peptide detection in biological fluids.

Overview

Note: An approved Letter of Intent (LOI) is required prior to the submission of a full proposal. The deadlines are indicated above. Breakthrough T1D Founded in 1970 by families whose loved ones had been diagnosed with type 1 diabetes (T1D), Breakthrough T1D is a tax-exempt nonprofit 501(c)3 organization. We are opening doors that were once closed by T1D diagnosis. We lead the way to more effective solutions by connecting the brightest minds to advance treatments, influence policy, and improve access to care.​ By driving innovation forward, Breakthrough T1D will make type 1 diabetes a condition of the past. Development of Continuous CPeptide Monitoring Technologies Summary Breakthrough T1D invites applications to develop continuous C-peptide monitoring (CCPM) technologies.Applications focused on early-stage development of sensor technologies, preclinical/feasibility studies and early-stage clinical evaluation of CCPM technologies will be considered.Applications may request up to $900,000 in total funding over a maximum period of three years. Applications of increased scope (time and/or budget) will be considered where there is a strong justification. Objectives Letters of Intent (LOIs) are sought from academic and industry applicants with innovative approaches to develop CCPM technologies. Examples of research appropriate for this RFA include, but are not limited to: Early-stage development of sensor technologies capable of continuous or high-frequency Cpeptide detection in biological fluids such as plasma or interstitial fluid.Preclinical development and validation of CCPM systems.Feasibility studies and early-stage clinical evaluation of CCPM technologies

Eligibility

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.